Literature DB >> 16306785

Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?

Elvio G Silva1, Michael T Deavers, Diane C Bodurka, Anais Malpica.   

Abstract

Low-grade endometrioid carcinomas, either of the endometrium or the ovaries, usually have an excellent prognosis. The association of this type of tumor with undifferentiated carcinoma is rare. In this study, we present the clinicopathologic features of 25 such cases. The age of the patients ranged from 30 to 82 years (median, 51 years). At presentation, the patients had either vaginal bleeding or pelvic pain. The endometrioid carcinoma involved the endometrium in 14 cases, the endometrium and 1 or both ovaries in 9 cases, and the ovaries in 2 cases. Undifferentiated carcinoma associated with low-grade endometrioid carcinoma was found at presentation in 19 grade 1 or 2 endometrioid carcinomas: 15 in the endometrium and 5 in the ovary. In one of these cases, undifferentiated carcinoma was found in the endometrium and the ovary. Undifferentiated carcinoma was found after resection of low-grade endometrioid carcinoma in six cases, involving the retroperitoneum, pelvis, vagina, or liver. The undifferentiated carcinoma was composed exclusively of diffuse sheets and solid nests of epithelial cells in l0 cases. Epithelial cells with isolated foci of keratinization were seen in nine cases and rhabdoid cells in a myxoid background in six cases. Twenty-four patients were treated with total abdominal hysterectomy and with bilateral salpingo-oophorectomy. Twenty-two patients received additional therapy as follows: chemotherapy (), radiotherapy (), and tamoxifen (). Follow-up showed that 15 patients died of disease in 1 to 60 months (median, 6 months), and 5 patients are alive with progressive disease with a follow-up between 6 and 8 months; 1 patient is alive with no evidence of disease at 104 months. In four cases, the diagnosis was made recently, with short follow-ups of 3 and 4 months. Foci of undifferentiated carcinoma may be confused with solid endometrioid adenocarcinoma erroneously leading to the diagnosis of a grade 3 or a significantly less aggressive grade 2 endometrioid carcinoma. The recognition of undifferentiated carcinoma in an otherwise low-grade endometrioid adenocarcinoma is extremely important because it indicates aggressive behavior. In asynchronous cases, being aware of this association can explain the absence of a second primary.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16306785     DOI: 10.1097/01.pgp.0000183048.22588.18

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  41 in total

1.  Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.

Authors:  Lien N Hoang; Yow-Shan Lee; Anthony N Karnezis; Basile Tessier-Cloutier; Noorah Almandani; Mackenzie Coatham; C Blake Gilks; Robert A Soslow; Colin J R Stewart; Martin Köbel; Cheng-Han Lee
Journal:  Histopathology       Date:  2016-07-05       Impact factor: 5.087

Review 2.  [New features in the 2014 WHO classification of uterine neoplasms].

Authors:  S F Lax
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

Review 3.  Low-grade endometrioid carcinoma of the ovary associated with undifferentiated carcinoma: case report and review of the literature.

Authors:  Ling Chen; Shujie Pang; Yan Shen; Zaiping Liu; Jing Luan; Yiquan Shi; Yixin Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Two cases of low-grade endometriod carcinoma associated with undifferentiated carcinoma of the uterus (dedifferentiated carcinoma): a molecular study.

Authors:  Giovanna Giordano; Tiziana D'Adda; Lorena Bottarelli; Mariano Lombardi; Francesca Brigati; Roberto Berretta; Carla Merisio
Journal:  Pathol Oncol Res       Date:  2011-03-30       Impact factor: 3.201

Review 5.  A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Authors:  Robert A Soslow; Rajmohan Murali
Journal:  Semin Diagn Pathol       Date:  2017-11-20       Impact factor: 3.464

Review 6.  [Un- and dedifferentiated endometrial carcinoma : A rare entity with a wide range of differential diagnosis].

Authors:  A K Höhn; C E Brambs; S Opitz; R Erber; A Hartmann; L-C Horn
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

7.  Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.

Authors:  Mackenzie Coatham; Xiaodong Li; Anthony N Karnezis; Lien N Hoang; Basile Tessier-Cloutier; Bo Meng; Robert A Soslow; C Blake Gilks; David G Huntsman; Colin J R Stewart; Lynne M Postovit; Martin Köbel; Cheng-Han Lee
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

8.  Molecular genetic heterogeneity in undifferentiated endometrial carcinomas.

Authors:  Juan M Rosa-Rosa; Susanna Leskelä; Eva Cristóbal-Lana; Almudena Santón; Ma Ángeles López-García; Gloria Muñoz; Belen Pérez-Mies; Michele Biscuola; Jaime Prat; Oliva Esther; Robert A Soslow; Xavier Matias-Guiu; Jose Palacios
Journal:  Mod Pathol       Date:  2016-08-05       Impact factor: 7.842

9.  Interobserver Variability in the Diagnosis of Uterine High-Grade Endometrioid Carcinoma.

Authors:  Sumi Thomas; Yaser Hussein; Sudeshna Bandyopadhyay; Michele Cote; Oudai Hassan; Eman Abdulfatah; Baraa Alosh; Hui Guan; Robert A Soslow; Rouba Ali-Fehmi
Journal:  Arch Pathol Lab Med       Date:  2016-05-03       Impact factor: 5.534

10.  Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas.

Authors:  Anthony N Karnezis; Lien N Hoang; Mackenzie Coatham; Sarah Ravn; Noorah Almadani; Basile Tessier-Cloutier; Julie Irving; Bo Meng; Xiaodong Li; Christine Chow; Jessica McAlpine; Kuan-Ting Kuo; Tsui-Lien Mao; Bojana Djordjevic; Robert A Soslow; David G Huntsman; C Blake Gilks; Martin Köbel; Cheng-Han Lee
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.